A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxelinduced dacryostenosis

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 419-423

  Leyssens, B ^a   Wildiers, H ^a   Lobelle, J P ^a   Gillis, A ^a   Paridaens, R ^a   Mombaerts, I ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Canalicular stenosis; Dacryostenosis; Docetaxel; Primary prevention; Tearing

Indexed keywords

ARTIFICIAL TEAR; CORTICOSTEROID; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DOCETAXEL; EYE DROPS; LACRYSTAT; METHYLPREDNISOLONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DACRYOSTENOSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EPIPHORA; EYE EXAMINATION; EYE TOXICITY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LACRIMAL DUCT OCCLUSION; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LACRIMAL GLAND DISEASE; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; STENOSIS, OCCLUSION AND OBSTRUCTION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTINEOPLASTIC AGENTS; CONSTRICTION, PATHOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACRIMAL APPARATUS DISEASES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; OPHTHALMIC SOLUTIONS; TAXOIDS; TREATMENT OUTCOME;

EID: 77951930986     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp319     Document Type: Article

References (14)

1. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (Taxotere): a newly recognized side effect. Ophthalmology 2001; 108: 994-995.
2. Esmaeli B, Hortobagyi GN, Esteva FJ et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002; 109: 1188-1191.
3. Tsalic M, Gilboa M, Visel B et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol 2003; 23(1): 57-61.
4. Esmaeli B, Amin S, Valero V et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006; 24(22): 3619-3622.
5. Esmaeli B, Ahmadi MA, Rivera E et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120: 1180-1182.
6. Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg 2003; 19: 305-308.
7. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 2001; 119: 1802-1804.
8. Esmaeli B, Hortobagyi G, Esteva F et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002; 13: 218-221.
9. Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006; 51: 19-40.
10. Calonge M. The treatment of dry eye. Surv Ophthalmol 2001; 45: 227-239.
11. Mombaerts I, Colla B. Modified Jones' lacrimal bypass surgery with an angled extended Jones' tube. Ophthalmology 2007; 114: 1403-1408.
12. Esmaeli B, Hidaji L, Adinin RB et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003; 98: 504-507.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10(1): 1-10.
14. Sparano JA, Wang M, Martino S et al. Weekly Paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358(16): 1663-1671.